Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enliven TherapeuticsELVN -1.43%31 Current Ratio is 64.07 as of Jun. 2026, which is 196% above its 10-year median of 21.65. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Enliven Therapeutics ranks better than 99.36% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Enliven Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 64.07.
Enliven Therapeutics has a current ratio of 64.07. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Enliven Therapeutics's Current Ratio or its related term are showing as below:
ELVN'
s Current Ratio Range Over the Past 10 Years
Min: 8 Med: 21.65 Max: 88.35
Current: 64.07
During the past 6 years, Enliven Therapeutics's highest Current Ratio was 88.35. The lowest was 8.00. And the median was 21.65.
ELVN's Current Ratio is ranked better than 99.36% of 1410
companies
in the Biotechnology industry
Industry Median: 3.85
vs ELVN: 64.07
Enliven Therapeutics (NAS:ELVN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Enliven Therapeutics Current Ratio Related Terms
Enliven Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Enliven Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELVN vs PBLS, CPRX, DNLI: Current Ratio Comparison
For the Biotechnology subindustry, Enliven Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics (ELVN) has a Current Ratio of 64.07 as of Jun. 2026. This is 196% above median its historical median of 21.65. Over the past decade, Enliven Therapeutics' Current Ratio has ranged from 8.00 to 88.35. According to the industry distribution chart, Enliven Therapeutics ranks #9 out of 1410 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Enliven Therapeutics' Current Ratio too high?
Enliven Therapeutics' current Current Ratio of 64.07 is 196% above median its 10-year median of 21.65. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 88.35. The Biotechnology industry median Current Ratio is 3.85. Enliven Therapeutics' value of 64.07 is 1564.2% above this industry median. Based on the distribution chart, Enliven Therapeutics ranks #9 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' Current Ratio compare to PBLS and CPRX?
According to the Biotechnology industry distribution chart, Enliven Therapeutics ranks #9 out of 1410 companies for Current Ratio. This places Enliven Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Enliven Therapeutics' value of 64.07 is 1564.2% above this benchmark. Historically, Enliven Therapeutics' own Current Ratio has ranged from 8.00 to 88.35 over the past decade. While the company's 10-year median is 21.65 vs. the industry median of 3.85, Enliven Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enliven Therapeutics's current Current Ratio of 64.07 is 1564.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enliven Therapeutics's current Current Ratio is 64.07, which is 196% above median its own 10-year median of 21.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current Current Ratio of 64.07. The current Current Ratio is 64.07, which is 196% above median its 10-year median of 21.65 and 1564.2% above the Biotechnology industry median of 3.85. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current Current Ratio is 64.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score
Get the complete analysis for ELVN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELVN has been successfully added to your 
